Why is Cohance Life falling/rising?

As of 16-Jul, Cohance Lifesciences Ltd has seen its stock price rise to 1,061.50, reflecting an increase of 8.3 points or 0.79%. The stock has been on an upward trend, gaining for the last six consecutive days and achieving a total return of 8.26% during this period. It has outperformed its sector by 1.06% today. Over the past week, the stock has risen by 6.68%, while its one-year performance shows a significant return of 22.99%, which is notably higher than the market's return of 2.38%. The company benefits from high management efficiency, evidenced by a return on equity (ROE) of 22.91%, and a low debt-to-equity ratio, contributing positively to investor sentiment.
In the broader market context, the stock's short-term performance has significantly outpaced the benchmark, with a 6.68% increase over the past week compared to a decline of 1.08% in the Sensex. Despite this positive momentum, there are concerns regarding the company's long-term growth potential, as indicated by a negative annual growth rate of operating profit over the last five years and a recent decline in profit after tax. These factors, combined with a high price-to-book value ratio, suggest that while the stock is currently rising, there are underlying issues that could impact its future performance.